BC Week In Review | Jan 5, 2018
Clinical News

Odonate starts Phase III trial of tesetaxel to treat breast cancer

Odonate Therapeutics Inc. (NASDAQ:ODT) began the Phase III CONTESSA trial of tesetaxel (DJ-927) to treat locally advanced or metastatic breast cancer. The open-label, international trial will compare 27 mg/m 2 oral tesetaxel once every 21...
BC Week In Review | Dec 14, 2017
Financial News

Odonate raises $150M IPO

Odonate Therapeutics Inc. (NASDAQ:ODT) raised $150 million late Dec. 6 through the sale of 6.3 million shares at $24 in an IPO underwritten by Goldman Sachs, Jefferies and Cowen. The IPO price values the company...
BC Extra | Dec 8, 2017
Financial News

Odonate down after $150M IPO

Odonate Therapeutics Inc. (NASDAQ:ODT) closed the week down at $22.67 after it raised $150 million late Wednesday through the sale of 6.3 million shares at $24 in an IPO underwritten by Goldman Sachs, Jefferies and...
BC Week In Review | Nov 17, 2017
Financial News

Odonate proposes $172.5M IPO

On Nov. 13, cancer company Odonate Therapeutics LLC (San Diego, Calif.) proposed to raise up to $175.5 million in an IPO on NASDAQ underwritten by Goldman Sachs, Cowen and Jefferies. This quarter, Odonate plans to...
BC Week In Review | Aug 6, 2012
Company News

Genta cancer news

Genta said it intends to file for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. At March 31, the company had $2.6 million in cash and a three-month net operating...
BC Extra | Aug 3, 2012
Company News

Genta files for Chapter 7 bankruptcy

Cancer company Genta Inc. (OTCBB:GNTA) said it intends to file for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. At March 31, the company had $2.6 million in cash and...
BC Week In Review | Jun 25, 2012
Clinical News

Tesetaxel: SPA received

Genta said it reached an agreement with FDA on an SPA and received scientific advice from EMA for a Phase III trial to evaluate tesetaxel as a single agent in metastatic breast cancer patients. The...
BC Week In Review | Jun 11, 2012
Clinical News

Tesetaxel: Phase IIb started

Genta began an open-label, international Phase IIb trial to compare 27 mg/m 2 oral tesetaxel on day 1 of a 21-day cycle or 15 mg/m 2 oral tesetaxel on days 1, 8 and 15 of...
BC Week In Review | Jun 4, 2012
Clinical News

Tesetaxel: Additional Phase IIb data

Additional data from 44 evaluable patients in an open-label, U.S. Phase IIb trial showed that tesetaxel produced 1 complete response and 19 partial responses. The DCR was 82%. Furthermore, tesetaxel produced a response in 49%...
BC Week In Review | May 14, 2012
Clinical News

Tesetaxel: Phase II started

Genta began the double-blind, placebo-controlled, international Phase II TESEGAST trial to compare 27 mg/m 2 oral tesetaxel on day 1 of a 21-day cycle in combination with Xeloda capecitabine vs. Xeloda alone in about 260...
Items per page:
1 - 10 of 490
BC Week In Review | Jan 5, 2018
Clinical News

Odonate starts Phase III trial of tesetaxel to treat breast cancer

Odonate Therapeutics Inc. (NASDAQ:ODT) began the Phase III CONTESSA trial of tesetaxel (DJ-927) to treat locally advanced or metastatic breast cancer. The open-label, international trial will compare 27 mg/m 2 oral tesetaxel once every 21...
BC Week In Review | Dec 14, 2017
Financial News

Odonate raises $150M IPO

Odonate Therapeutics Inc. (NASDAQ:ODT) raised $150 million late Dec. 6 through the sale of 6.3 million shares at $24 in an IPO underwritten by Goldman Sachs, Jefferies and Cowen. The IPO price values the company...
BC Extra | Dec 8, 2017
Financial News

Odonate down after $150M IPO

Odonate Therapeutics Inc. (NASDAQ:ODT) closed the week down at $22.67 after it raised $150 million late Wednesday through the sale of 6.3 million shares at $24 in an IPO underwritten by Goldman Sachs, Jefferies and...
BC Week In Review | Nov 17, 2017
Financial News

Odonate proposes $172.5M IPO

On Nov. 13, cancer company Odonate Therapeutics LLC (San Diego, Calif.) proposed to raise up to $175.5 million in an IPO on NASDAQ underwritten by Goldman Sachs, Cowen and Jefferies. This quarter, Odonate plans to...
BC Week In Review | Aug 6, 2012
Company News

Genta cancer news

Genta said it intends to file for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. At March 31, the company had $2.6 million in cash and a three-month net operating...
BC Extra | Aug 3, 2012
Company News

Genta files for Chapter 7 bankruptcy

Cancer company Genta Inc. (OTCBB:GNTA) said it intends to file for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. At March 31, the company had $2.6 million in cash and...
BC Week In Review | Jun 25, 2012
Clinical News

Tesetaxel: SPA received

Genta said it reached an agreement with FDA on an SPA and received scientific advice from EMA for a Phase III trial to evaluate tesetaxel as a single agent in metastatic breast cancer patients. The...
BC Week In Review | Jun 11, 2012
Clinical News

Tesetaxel: Phase IIb started

Genta began an open-label, international Phase IIb trial to compare 27 mg/m 2 oral tesetaxel on day 1 of a 21-day cycle or 15 mg/m 2 oral tesetaxel on days 1, 8 and 15 of...
BC Week In Review | Jun 4, 2012
Clinical News

Tesetaxel: Additional Phase IIb data

Additional data from 44 evaluable patients in an open-label, U.S. Phase IIb trial showed that tesetaxel produced 1 complete response and 19 partial responses. The DCR was 82%. Furthermore, tesetaxel produced a response in 49%...
BC Week In Review | May 14, 2012
Clinical News

Tesetaxel: Phase II started

Genta began the double-blind, placebo-controlled, international Phase II TESEGAST trial to compare 27 mg/m 2 oral tesetaxel on day 1 of a 21-day cycle in combination with Xeloda capecitabine vs. Xeloda alone in about 260...
Items per page:
1 - 10 of 490